Also known as: Winstrol, Androstanazole, Androstanazol, 10418-03-8, Stromba, Stanazolol
A synthetic steroid that has anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1194)
(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol
InChI=1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1
LKAJKIOFIWVMDJ-IYRCEVNGSA-N
CC12CCC3C(C1CCC2(C)O)CCC4C3(CC5=C(C4)NN=C5)C
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C
4R1VB9P8V3
Winstrol, Androstanazole, Androstanazol, 10418-03-8, Stromba, Stanazolol, Tevabolin, Winstrol Depot, Strombaject, Estazol, Winstroid, Winstrol V, Estanozolol, Stanozololum, Win 14833, Anabol, Stanozolol Ciii, Androstanazolestanazol, Nsc-43193, Win-14833, Nsc 233046, 4r1vb9p8v3, Chebi:9249, 17-methyl-2'h-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol, Nsc-233046, (1s,3as,3br,5as,10as,10bs,12as)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol, Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-, Stanozolo [dcit], Androstanazole (van), Stanozolo, Stanozolol (1'h Form), Winstrol-v, Stanozololum [inn-latin], Estanozolol [inn-spanish], (1s,2s,10s,13r,14s,17s,18s)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5-dien-17-ol, Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-, Hsdb 3185, Sr-05000001522, Stanozolol (2'h Form), 17?-methyl-5?-androstano[3,2-c]pyrazol-17?-ol, Einecs 233-894-8, Nsc 43193, Unii-4r1vb9p8v3, 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-androstano(3,2-c)pyrazole, Winstrol (tn), 2'h-androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-, 17-methyl-5alpha-androstano(3,2-c)pyrazol-17beta-ol, 302-96-5, Stanozolol [usan:usp:inn:ban:jan], 17-beta-hydroxy-17-alpha-methylandrostano(3,2-c)pyrazole, 17beta-hydroxy-17alpha-methyl-androstano(3,2-c)pyrazole, 17-methyl-pyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol, 17-methylpyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol, 17beta-hydroxy-17-methyl-5alpha-androstano(3,2-c)pyrazole, Stanozolol [mi], 17alpha-methyl-17beta-hydroxy-5alpha-androstano(3,2-c)pyrazole, Stanozolol [inn], Stanozolol [jan], 2'h-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol, 17-methyl-, 2,3-(4',3'-pyrazolo)-5alpha-androstan-17beta-ol, 17-methyl-, Stanozolol [hsdb], Stanozolol [usan], Stanozolol [vandf], Stanozolol [mart.], Dsstox_cid_24128, Dsstox_rid_97564, Stanozolol [who-dd], Stanozolol--dea Schedule Iii, Dsstox_gsid_44128, Schembl44099, Schembl44100, Stanozolol (jan/usp/inn), 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol, Mls001424321, 17-methyl-2'h-5.alpha.-androst-2-eno(3,2-c)pyrazol-17.beta.-ol, Stanozolol, Analytical Standard, Stanozolol [green Book], Chembl2079587, Dtxsid3044128, Stanozolol [orange Book], Gtpl10369, Stanozolol [ep Monograph], Stanozolol Ciii [usp-rs], Hms2052h11, Hms2090p03, Hms3713k06, Stanozolol [usp Monograph], Bcp12548, Hy-b0899, Nsc43193, Win14833, Zinc4097376, Tox21_113993, 1'h-androstano(3,2-c)pyrazol-17-ol, 17-methyl-, (5-alpha,17-beta)-, Akos005067278, Stanozolol 1.0 Mg/ml In Acetonitrile, Am84316, Ccg-101186, Ccg-220452, Cs-4363, Db06718, Nc00436, Ncgc00344550-01, (1s,3as,3br,5as,10as,10bs,12as)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol, Ac-16140, Ac-33164, As-35198, Cpd000058878, Smr000058878, Cas-10418-03-8, C07311, D00444, 17-methyl-5a-androstano[3,2-c]pyrazol-17b-ol, Ab00443942-03, Ab00443942-05, 418s038, Sr-05000001522-1, Sr-05000001522-2, W-108823, 17a-methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole, 17b-hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole, 17b-hydroxy-17a-methyl-5a-androstano[3,2-c]pyrazole, Q63409446, 17-methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol, Z1541662177, 17-methyl-1'h-5alpha-androstano[3,2-c]pyrazol-17beta-ol, Stanozolol, European Pharmacopoeia (ep) Reference Standard, (5a,17b)-17-methyl-2'h-androst-2-eno[3,2-c]pyrazol-17-ol, 2,3'-pyrazolo)-5.alpha.-androstan-17.beta.-ol, 17-methyl-, 5alpha-androstane-17alpha-methyl-17beta-ol-[3,2-c]pyrazole, 17-methyl-5.alpha.-androstano(3,2-c)pyrazol-17.beta.-ol, 2'h-5a-androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8ci), 17alpha-methyl-17beta-hydroxy-5alpha-androst-2-eno(3,2-c)-pyrazole, 1'h-androstano(3,2-c)pyrazol-17-ol, 17-methyl-, (5.alpha.,17.beta.)-, 2'h-androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5.alpha.,17.beta.), Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'h-androst-2-eno[3,2-c]pyrazol-17-ol Deriv., (1s,2s,10s,13r,14s,17s,18s)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol, 17966-55-1, 875293-72-4, Cyclopenta[7,3-c]pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-
2005-03-26
Anabolic Steroids
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Stanozolol ... /is/ indicated in conditions such as chronic infections, extensive surgery, corticosteroid-induced myopathy, decubitus ulcers, burns, or severe trauma, which require reversal of catabolic processes or protein-sparing effects. /This agent is/ ... adjunct to, and not replacement for, conventional treatment of these disorders. /NOT included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 140
Stanozolol is effective in raising hemoglobin concentrations in some cases of aplastic anemia (congenital or idiopathic). /NOT included in US product labeling/
Stanozolol ... /is/ indicated in the prophylaxis of hereditary angioedema to decrease the frequency and severity of attacks. /Included in US product labeling/
For more Therapeutic Uses (Complete) data for STANOZOLOL (10 total), please visit the HSDB record page.
Vet: monitor benefits and need carefully in cardiac disease and nephritis.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 553
Use of anabolic steroids by athletes is not recommended. Objective evidence is conflicting and inconclusive as to whether these medications significantly increase athletic performance by increasing muscle strength. Weight gains reported by athletes are due in part to fluid retention, which is a potentially hazardous side effect of anabolic steroid therapy. The risk of other unwanted effects, such as testicular atrophy and suppression of spermatogenesis in males; menstrual disturbances and virilization, such as deepening of voice, development of acne, and unnatural growth of body hair in females; peliosis hepatis or other hepatotoxicity; and hepatic cancer outweigh and possible benefit received from anabolic steroids and make their use in athletes inappropriate. /Anabolic steroids/
Thomson.Microm
